Prostate Cancer P D:前列腺癌患者前列腺切除术后男性的死亡日期和死因调查

2019-05-10 AlexYang MedSci原创

国家死亡指数(NDI)是一个集中式的数据库,包含了死亡证明相关信息,这些信息被健康和医疗调查人员用来参考确定人口动态统计情况。然而,该数据库经常包含错误的死因。由于NDI依赖于前列腺癌(PC)患者根治性前列腺切除(RP)相关研究的治疗结果数据,最近,有研究人员通过参考SEARCH数据库的死亡数据来确定NDI数据的可靠性。研究发现,在SEARCH中共有1312名男性死亡,然而,NDI却报道这些男性的

国家死亡指数(NDI)是一个集中式的数据库,包含了死亡证明相关信息,这些信息被健康和医疗调查人员用来参考确定人口动态统计情况。然而,该数据库经常包含错误的死因。由于NDI依赖于前列腺癌(PC)患者根治性前列腺切除(RP)相关研究的治疗结果数据,最近,有研究人员通过参考SEARCH数据库的死亡数据来确定NDI数据的可靠性。

研究发现,在SEARCH中共有1312名男性死亡,然而,NDI却报道这些男性的17%仍旧存活。在SEARCH和NDI数据库中一致的1093名男性死亡数据中,死亡匹配日期准确匹配、1天、1周或者31天的比例分别为94%、97%、99%和100%。在SEARCH数据库中,那些因前列腺癌死亡的105名男性中,12%的男性在NDI数据库中记录为死于非前列腺癌。同时,在NDI中被记录为死于PC(n=139)的患者中,34%的患者在SEARCH记录为死于非前列腺癌。

最后,研究人员指出,他们的发现阐释了NDI能够提供死亡的精确日期,但是否由于前列腺癌引起死亡却经常出错。因此,研究人员认为依赖于NDI数据库的相关研究可能是不可靠的。

原始出处:

Drew Moghanaki, Lauren E. Howard, Amanda De Hoedt et al. Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer P D. 29 Apr 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
    2019-05-12 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
    2019-05-12 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
    2019-05-11 一个字-牛

    学习了谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1877146, encodeId=aa1b18e714607, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Nov 05 02:38:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791577, encodeId=d5b31e9157783, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Mar 20 22:38:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708849, encodeId=8e561e0884907, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue May 14 19:38:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364483, encodeId=6f4813644839f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602152, encodeId=036e160215207, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 12 04:38:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366058, encodeId=be9b366058ac, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat May 11 21:48:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040450, encodeId=06b71040450fb, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri May 10 16:38:00 CST 2019, time=2019-05-10, status=1, ipAttribution=)]
    2019-05-10 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:接受治疗的前列腺癌患者心血管事件风险

由此可见,生活方式、人体测量学指标或心血管危险因素并未解释接受姑息治疗的PCa患者的IS和HF风险。结果强调了在该患者组中平衡疾病管理和监测心血管健康的必要性。

Cancer:糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险

尽管糖尿病与前列腺癌(PC)风险呈现负相关关系,但是血糖控制对PC进展的的影响仍旧未知。最近,有研究人员在经历根治性前列腺切除(RP)男性糖尿病患者中,探究了血红蛋白A1c(HbA1c)和长期PC结果之间的相关性。研究共有1409名男性,其中699名患者(50%)HbA1c值<6.5%,631名(45%)患者的HbA1c值为6.5%到7.9%之间,79名(6%)患者的HbA1c值不小于8%。

降低肿瘤转移和死亡风险近60%,前列腺癌新药获优先审评资格

拜耳(Bayer)公司和Orion公司宣布,美国FDA接受了该公司为雄激素受体(AR)拮抗剂darolutamide递交的新药申请(NDA),用于治疗非转移性去势抵抗性前列腺癌(nmCRPC)患者。

2019年AUA:临床前数据突显EPI-7386治疗前列腺癌的潜力

ESSA是一家专注于开发前列腺癌治疗新疗法的制药公司,近日宣布,将在2019年美国泌尿学会(AUA)年会上公布新一代N末端域雄激素受体抑制剂EPI-7386在去势抵抗前列腺癌模型中的有效性数据。

Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查

美国食品和药物管理局(FDA)已接受新的药物申请审查,并给予darolutamide优先审查。